

Cover Story
A move by Genentech has eliminated discounts and rebates hospitals receive when they purchase three of the company's top-selling infused cancer drugs.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - NCI releases names of members of ad hoc working group—filling the void left by BSA
- ACOG says it will no longer accept federal funding
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer
- Bhattacharya: New grant review criterion is “not political”
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”